Dr. Rene Y. McNall-Knapp
Claim this profileUniversity of Oklahoma Health Sciences Center
Expert in Tumors
Expert in Brain Tumor
71 reported clinical trials
126 drugs studied
About Rene Y. McNall-Knapp
Education:
- Obtained MD (Doctor of Medicine) from the University of Oklahoma College of Medicine, 2008.
- Completed Residency in Internal Medicine at the University of Oklahoma Health Sciences Center, 2011.
- Finished Fellowship in Hematology/Oncology at the University of Oklahoma Health Sciences Center, 2014.
Experience:
- Currently serves as an Assistant Professor in the Department of Medicine, Division of Hematology/Oncology, at the University of Oklahoma Health Sciences Center.
Area of expertise
1Tumors
Global LeaderStage IV
NTRK1 positive
NTRK positive
2Brain Tumor
Global LeaderStage I
Stage II
Stage IV
Affiliated Hospitals
Clinical Trials Rene Y. McNall-Knapp is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
More about Rene Y. McNall-Knapp
Clinical Trial Related7 years of experience running clinical trials · Led 71 trials as a Principal Investigator · 30 Active Clinical TrialsTreatments Rene Y. McNall-Knapp has experience with
- Cyclophosphamide
- Radiation Therapy
- Doxorubicin Hydrochloride
- Etoposide
- Nivolumab
- Vincristine Sulfate
Breakdown of trials Rene Y. McNall-Knapp has run
Tumors
Brain Tumor
Lymphoma
Neuroblastoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rene Y. McNall-Knapp specialize in?
Rene Y. McNall-Knapp focuses on Tumors and Brain Tumor. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are NTRK1 positive.
Is Rene Y. McNall-Knapp currently recruiting for clinical trials?
Yes, Rene Y. McNall-Knapp is currently recruiting for 22 clinical trials in Oklahoma City Oklahoma. If you're interested in participating, you should apply.
Are there any treatments that Rene Y. McNall-Knapp has studied deeply?
Yes, Rene Y. McNall-Knapp has studied treatments such as Cyclophosphamide, Radiation Therapy, Doxorubicin Hydrochloride.
What is the best way to schedule an appointment with Rene Y. McNall-Knapp?
Apply for one of the trials that Rene Y. McNall-Knapp is conducting.
What is the office address of Rene Y. McNall-Knapp?
The office of Rene Y. McNall-Knapp is located at: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104 United States. This is the address for their practice at the University of Oklahoma Health Sciences Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.